Global Soluble Fibers Market

Digestive enzymes refer to compounds that aid in digestion by assisting with food breakdown. These proteins accelerate the chemical processes that transform food into compounds that can be absorbed by the digestive system. The salivary glands and the cells lining the stomach, pancreas, and small intestine produce (release) them. The main types of digestive enzymes are carbohydrates, protease, lipase, and other enzyme types. Lipase is a protein produced by the pancreas; a small organ located near the stomach that aids in fat digestion. The enzymes originated from animals, fungi, microbial, and plants that are used for indigestion, chronic pancreatitis, irritable bowel syndrome, and other applications. The various distribution channel includes retail stores and online stores. The digestive enzymes market research report is one of a series of new reports from The Business Research Company that provides digestive enzymes market statistics, including digestive enzymes industry global market size, regional shares, competitors with a digestive enzymes market share, detailed digestive enzymes market segments, market trends and opportunities, and any further data you may need to thrive in the digestive enzymes industry. This digestive enzymes market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global digestive enzymes market grew from $0.82 billion in 2022 to $0.89 billion in 2023 at a compound annual growth rate (CAGR) of 9.2%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The digestive enzymes market is expected to grow from $1.32 billion in 2027 at a CAGR of 10.3%. The rising prevalence of the gastrointestinal disorder among different age groups drives the growth of the digestive enzymes market. Gastrointestinal disorders include disorders in the gastrointestinal tract starting from the mouth, oesophagus, stomach, small intestine, large intestine, and anus caused due to lack of digestive enzymes. Gastrointestinal disorders require the digestive enzymes to be taken orally as a dietary supplement or as a drug. The increased rates of gastrointestinal disorders are linked to smoking, diet and genetics, sanitation, increased use of antibiotics, and the changing environmental factors due to industrialization and urbanization. According to the American Gastroenterological Association’s survey published in April 2020 on the worldwide prevalence and burden of functional gastrointestinal disorders, among 73,076 adult respondents, about 40.3% of people met the diagnostic criteria for at least 1 functional gastrointestinal disorder (FGIDs). FGID was more prevalent among women than men. A large-scale multinational study found that more than 40% of the population is having FGIDs across the globe. Therefore, the increase in the prevalence of digestive diseases contributes to the growth of the market. The potential side effects of digestive enzyme supplements and drugs restrain the growth of the digestive enzymes market. Continuous intake of digestive enzymes increases dependency on the digestive enzymes resulting in a weaker digestive system over time. The weakened digestive system leads to digestive distress, gas, nausea, bloating, decreased stomach acid, and allergic reactions accompanied by diarrhea and vomiting. For instance, the digestive enzyme bromelain causes thinning of the blood and increases the risk of excess bleeding. The thinning of the blood is the result of the anti-platelet activity caused by the drug. Thus, the side effects caused by the excess and continuous intake of digestive enzymes negatively impact the growth of the digestive enzyme market. The companies in the digestive enzymes market are investing in developing customized digestive enzymes. These customized digestive enzymes are condition-specific enzymes to support digestion for digestive sensitive patients and may contain multiple enzymes in the same product. The companies involved in manufacturing digestive enzymes are developing customized digestive enzymes to ease the digestion of different types of food. For instance, Sabinsa, a USA-based provider of herbal extracts, cosmeceuticals, minerals, and dietary supplements, formulated DigeZyme. DigeZyme is a multi-enzyme complex comprising five different enzymes, namely, cellulase, lactase, amylase, lipase, and protease. It is widely used by people who have difficulty in digesting carbohydrates, fats, and proteins, respectively. The companies are increasingly investing in developing customized digestive enzymes. In January 2020, Nestlé, a Switzerland-based food and drink processing corporation, entered into an asset purchase agreement with Allergan, an Ireland-based pharmaceutical company that acquires, develops, and markets brand name drugs, to acquire Zenpep for an amount undisclosed. Through the acquisition, Nestle aims to expand its medical nutrition portfolio by including Zenpep products to support food ingestion, digestion, and absorption. Zenpep is a medication for people who cannot digest food properly due to the lack of digestive enzymes. Major players in the digestive enzymes market are Garden of Life, Biotics Research Corporation, Klaire Laboratories, Abbott Nutrition, AbbVie Inc., Allergan PLC., Johnson & Johnson Inc. Amway Corporation, Food State Inc., Matsun Nutrition, Metagenics Inc., Twinlab Corporation, Food State Inc., AST Enzymes, VEMO 99 OOD, Advanced Vital Enzymes Pvt. Ltd., Zeus Biotech Limited, Vox Nutrition Inc., Enzyme Bioscience Pvt. Ltd., Metagenics, XYMOGEN Inc., Douglas Laboratories, Thorne Research, Integrative Therapeutics LLC., Pure Encapsulations, Ortho Molecular Products Inc., Designs for Health Inc., Master Supplements Inc., and Proteozymes. North America was the largest region in the digestive enzymes market in 2022. Middle East is expected to be the largest growing region in the global digestive enzymes market during the forecast period. The regions covered in the global digestive enzymes market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the digestive enzymes market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The digestive enzymes market consists of sales of amylase, maltase, and lactase. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global digestive enzymes market is segmented - 1) By Enzyme Type: Carbohydrates, Protease, Lipase, Other Enzyme Types 2) By Origin: Animal, Fungi, Microbial, Plant 3) By Application: Indigestion, Chronic Pancreatitis, Irritable Bowel Syndrome, Other Applications 4) By Distribution Channel: Retail Stores, Online Stores

Digestive health supplements refer to a nutritional supplement that aids in the breakdown of food and liquids into their chemical constituents—carbohydrates, lipids, proteins, and the like—so that the body may absorb them as nutrients and utilise them for energy, cell growth, and repair, and other functions.       The main products in the digestive health supplements market are prebiotics, probiotics, enzymes, fulvic acid, and other products. Prebiotics refer to a type of carbohydrate, mostly fibers, that humans cannot digest but are digestible by their gut bacteria. The main forms include capsules, tablets, powders, liquids, and other forms. They are sold through various distribution channels such as supermarkets or hypermarkets, convenience stores, specialty stores, pharmacies, e-commerce, and other distribution channels. The digestive health supplements market research report is one of a series of new reports from The Business Research Company that provides digestive health supplements market statistics, including digestive health supplements industry global market size, regional shares, competitors with a digestive health supplements market share, detailed digestive health supplements market segments, market trends and opportunities, and any further data you may need to thrive in the digestive health supplements industry. This digestive health supplements market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global digestive health supplements market size grew from $14.02 billion in 2022 to $15.46 billion in 2023 at a compound annual growth rate (CAGR) of 10.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The digestive health supplements market size is expected to grow to $22.69 billion in 2027 at a CAGR of 10.1%. The rising prevalence of digestive diseases is expected to propel the growth of the digestive health supplement market going forward. A digestive disease is any health problem that affects the digestive tract. These problems can range from mild to severe. Digestive health supplements like probiotics, prebiotics, and enzymes help with digestive problems like diarrhea, constipation, inflammatory bowel disease, irritable bowel disease, urinary tract infection, and other gastrointestinal-related digestive problems. For instance, according to the International Foundation for Gastrointestinal Disorders, irritable bowel syndrome is the most common functional GI disorder, with a prevalence rate of 10–15% globally. Additionally, it is one of the most common conditions that require a visit to the doctor. Thus, the rising prevalence of digestive diseases will increase sales and awareness of digestive health supplements, thereby, driving the growth of the digestive health supplement market. Product innovation is the key trend gaining popularity in the digestive health supplements market. Major companies operating in the market are introducing technological innovations such as new ingredients and exploring innovative administration forms to cater to the needs of various age groups to sustain their position in the market. For instance, in April 2021, Bausch Health Companies Inc., a US-based pharmaceutical company, launched a unique proprietary blend of five probiotic strains ingredients, ENVIVE, an over-the-counter probiotic supplement that is formulated to strengthen and protect the digestive system. In May 2022, Glanbia Nutritionals, an Ireland-based nutrition company, acquired Sterling Technology for an amount of $60 million. Through this acquisition, Glanbia Nutritionals aims to scale and strengthen its bioactive solutions portfolio to cater to the needs of its customers. Sterling Technology is a US-based bioactive solution manufacturing company, which offers product solutions in digestive health, Tegricel, a solution that uses NSAIDs to keep the digestive tract healthy. Major players in the digestive health supplements market are Amway Corp, Bayer AG, Pfizer Inc., NOW Foods, Alimentary Health Limited, Nestle, Nutricia, Lonza, Nature’s Bounty, Garden of Life, Zenwise, OLLY Public Benefit Corporation, BASF SE, Herbalife International, and GlaxoSmithKline PLC North America was the largest region in the digestive health supplements market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in digestive health supplements market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the digestive health supplements market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The digestive health supplements market consists of sales of L-glutamine, Slippery elm, Ginger root, and vitamin D. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global digestive health supplements market is segmented - 1) By Product: Prebiotics, Probiotics, Enzymes, Fulvic Acid, Other Product 2) By Form: Capsules, Tablets, Powders, Liquids, Other Form 3) By Distribution Channel: Supermarkets/Hypermarkets, Convenience Store, Specialty Store, Pharmacies, E-Commerce, Other Distribution Channels

Digestive health is a system that enables the body to efficiently digest food and absorb nutrients, maintaining overall health. Constipation, heartburn, bloating, indigestion, and other digestive issues are less common in those with sound digestion, as are more severe digestive illnesses. The main types of digestive health products are functional foods and beverages, vitamins and dietary supplements, and other products. The functional foods and beverages offer health benefits beyond their nutritional value. Functional food and beverages are products that have an added physiological benefit above and beyond their naturally occurring benefits. The various ingredient used in digestive health products are probiotics, prebiotics, digestive enzymes, and other ingredients. The digestive health products are distributed through supermarkets/hypermarkets, hospital pharmacies, online pharmacies, and other distribution channels. The digestive health market research report is one of a series of new reports from The Business Research Company that provides digestive health market statistics, including digestive health industry global market size, regional shares, competitors with a digestive health market share, detailed digestive health market segments, market trends and opportunities, and any further data you may need to thrive in the digestive health industry. This digestive health market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global digestive health market size grew from $49.3 billion in 2022 to $55.7 billion in 2023 at a compound annual growth rate (CAGR) of 13.0%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The digestive health market size is expected to grow to $84.45 billion in 2027 at a CAGR of 11.0%. The rising geriatric population is driving the digestive health market. The geriatric population consists of adults 65 years of age and older. The digestive system may not function as swiftly or as efficiently as it once did as people age because numerous biological processes slow down with advancing years. The muscles in the digestive system become stiffer, softer, and less effective over time. Digestive health products aid the body in efficiently digesting food and absorbing nutrients, maintaining overall health. For instance, in June 2020, according to a study by the United Nations, the total number of people age 80 years and above is expected to increase from 143 million in 2019 to over 426 million in 2050. Therefore, the increasing geriatric population is expected to aid the growth of the compression therapy market. New product innovation is a key trend in the digestive health market. Detoxification is gaining popularity, which is being taken as an opportunity by major digestive health companies. A series of procedures known as detoxification is intended to treat acute intoxication and withdrawal. For instance, in August 2022, JP Holistic Nutrition, a UK-based online pet supplement store, launched Urban Retreat RESET. Urban Retreat Reset detox is a beverage for digestion and gut health. Digestive enzymes, probiotics, and prebiotics are all ingredients in this supplement for digestive health. It conatins alkalizing products that enhance wellbeing, sleep, mood regulation, and brain health. In March 2021, PanTheryx, the colostrum-based nutrition and biotechnology company, acquired TruBiotics from Bayer HealthCare LLC for an undisclosed amount. Through this acquisition, PanTheryx will expand its product portfolio in the probiotics and microbiome category. TruBiotics is a probiotic brand of Bayer AG, a German multinational pharmaceutical and biotechnology company, that specialises in nutritional supplements, including probiotics. Major players in the digestive health market are Chr. Hansen Holdings A/S, Yakult Honsha Co. Ltd., Nestle SA, DuPont, PepsiCo Inc., Danone A.S., Cargill Inc., General Mills, Inc., Arla Foods, Inc., Mondelez International Inc., Deerland Probiotics & Enzymes, Inc., Sanofi, BASF SE, Bayer AG and AST Enzymes. North America was the largest region in the digestive health market in 2022. The regions covered in the digestive health market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the digestive health market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The digestive health market includes revenues earned by entities by food enzymes and microbial-based ingredients. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global digestive health market is segmented - 1) By Product Type: Functional Foods and Beverages, Vitamins and Dietary Supplements, Other Products 2) By Ingredient Type: Probiotics, Prebiotics, Digestive Enzymes, Other Ingredients 3) By Distribution Channel: Supermarkets/Hypermarkets, Hospital Pharmacies, Online Pharmacies, Other Distribution Channels

The digestive and intestinal remedy refers to medications that can treat gastrointestinal disorders such as stomach upset, constipation, and diarrhoea. It uses classes of drugs such as antacids, proton pump inhibitors, and histamine2 blockers during the treatment process. The main types of digestive and intestinal remedies are digestive medicines, remedies against gastrointestinal complaints, and natural and synthetic agents. Digestive medicines consist of digestive enzymes, which are organic compounds required by the body to aid in the breakdown and digestion of meals. Digestive medicine helps treat occasional heartburn, nausea, and upset stomach. These are used by differnet age group such as pediatric, adults, and sold through various distribution channel such as online and offline. The digestive and intestinal remedies market research report is one of a series of new reports from The Business Research Company that provides digestive and intestinal remedies market statistics, including digestive and intestinal remedies industry global market size, regional shares, competitors with a digestive and intestinal remedies market share, detailed digestive and intestinal remedies market segments, market trends and opportunities, and any further data you may need to thrive in the digestive and intestinal remedies industry. This digestive and intestinal remedies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global digestive and intestinal remedies market size is expected to grow from $19.49 billion in 2022 to $20.46 billion in 2023 at a compound annual growth rate (CAGR) of 4.9%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, and affecting many markets across the globe. The digestive and intestinal remedies market size is expected to reach $24.44 billion in 2027 at a CAGR of 4.5%. The increase in gastrointestinal disorder cases is expected to propel the digestive and intestinal remedy market going forward. Gastrointestinal disorders refer to a collective term of diseases such as nausea, vomiting, food poisoning, and diarrhea that impact the overall biological functioning of the gastrointestinal (GI) tract. The rising incidence of gastrointestinal disorders has resulted in a growing demand for digestive and intestinal remedies that can treat gastrointestinal diseases effectively. For instance, in April 2020, according to a survey by the American Gastroenterological Association covering 33 countries on 6 continents regarding the prevalence of and factors associated with functional gastrointestinal disorders, among the 73,076 adult respondents, more than 40% of persons worldwide have FGIDs, which affect the quality of life and health care use. Additionally, in May 2020, News Medical, a UK-based open-access medical information company, said four people worldwide experience functional gastrointestinal diseases of varying severity for every 10 adults. Therefore, an increase in gastrointestinal disorder cases is expected to drive the digestive and intestinal remedy market. Technological developments and advancements are key trend gaining popularity in the digestive and intestinal remedy market. Major players operating in the digestive and intestinal remedy market are focused on creating innovative technologies to manage and monitor digestive health in the digestive and intestinal remedy market. Recently the market has witnessed the use of breath analyzers to gather clinical condition information related to the digestive system. For instance, In May 2021, Owlstone Medical, a UK-based manufacturer and developer of breathalyzer for disease, launched digestive health breath testing in collaboration with functional gut diagnostics and functional gut clinic, providers of smart solutions for the diagnosis of gut health problems. Individuals can get better control over their digestive health through a simple at-home breath test. In SIBO and Food Intolerance, hydrogen and methane are well-established breath-based indicators. It uses an external substrate to create a precise and biologically relevant measurement of breath. In February 2020, Takeda Pharmaceutical Company Limited, a Japan-based pharmaceutical company,  acquired PVP Biologics, Inc. for $300 million. Through this acquisition, Takeda increased its targeted therapy-based product portfolio for digestive diseases and research and development capabilities in the field of gastrointestinal disorders. PVP Biologics, Inc. is a US-based pharmaceutical company specializing in developing medicines for treating digestive and intestinal remedies diseases. Major players in the digestive and intestinal remedies market are Bayer AG, Johnson & Johnson, GlaxoSmithKline Plc., Procter & Gamble Company, Sanofi SA, CH Boehringer Sohn AG & Co KG, Reckitt Benckiser Group plc, Abbott Laboratories, Takeda Pharmaceutical Company Limited, Menarini Group, Bausch Health Companies Inc., Eli Lilly and Company, Jiangzhong Pharmaceutical Co Ltd., Merck KGaA, Pfizer Inc., and Prestige Consumer Healthcare Inc. North America was the largest region in the digestive and intestinal remedies market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the digestive and intestinal remedies report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the digestive and intestinal remedies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The digestive and intestinal remedies market consists of sales of antacids, prokinetic agents, laxatives, antidiarrheal agents, generic enzymes. Values in this market are "factory gate" values that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global digestive and intestinal remedies market is segmented - 1) By Type: Digestive Medicines, Remedies Against Gastrointestinal Complaints, Natural And Synthetic Agents 2) By Age Group: Pediatric, Adults 3) By Distribution Channel: Online, Offline

Functional foods are highly nutritious foods that are associated with many health benefits. The benefits include prevention against nutrition deficiencies, protection against diseases, improved cholesterol levels, lower blood pressure, and promotion of proper growth & development. The main product types are bakery & cereals, dairy products, meat, fish & eggs, soy products, fats & oils, and other product types. A dairy product is milk and any of the foods made from milk, including butter, cheese, ice cream, yogurt, and condensed and dried milk. The ingredients used for functional foods are carotenoids, dietary fibers, fatty acids, minerals, prebiotics, probiotics, vitamins, and other product types. The various applications of these food products are sports nutrition, weight management, immunity, digestive health, clinical nutrition, cardio health, and other product types. The functional food research report is one of a series of new reports from The Business Research Company that provides functional food statistics, including functional food industry global market size, regional shares, competitors with functional food share, detailed functional food segments, market trends and opportunities, and any further data you may need to thrive in the functional food industry. This functional food research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global functional foods market size will grow from $203.64 billion in 2022 to $229.7 billion in 2023 at a compound annual growth rate (CAGR) of 12.8%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global functional foods market size is expected to grow from $354.96 billion in 2027 at a CAGR of 11.5%. The increasing number of diseases is shifting consumers' focus to healthy eating, which in turn is projected to boost the demand for functional foods. Functional food provides the human body with healthy nutrition, vitamins and minerals, and reduces the risk of diseases. According to the Centre for Disease Control and Prevention, heart disease is a leading cause of death in the USA, and about 6,47,000 Americans die from heart disease every year, which is one out of every four deaths. Therefore, the increasing number of cardiovascular and other diseases across the globe is anticipated to generate higher demand for a healthy diet, which in turn, is likely to propel the revenues of the functional food market over the forecast period. The higher price of functional food products attributed to the inclusion of healthier or natural ingredients is limiting the growth of the functional food market. Functional foods are sold at higher prices and hold larger profit margins than conventional foods. Functional foods are priced 30 to 500% higher than comparable conventional foods. Thus, the higher prices of functional food are to act as a major restraint for the growth of the functional food market over the forthcoming years. Key players dealing in the functional food market are increasingly focusing on new product developments and company expansion to meet the rising demand from consumers. For instance, in January 2022, Fonterra Co-operative Group Limited, New-Zealand-based dairy company, Tillamook Country Creamery Association (TCAA), and Three Mile Canyon Farm, introduced Pro-Optima TM, A-grade functional whey protein concentrate. Pro-Optima TM can be used in cultured products such as yogurt, to enhance the textures to deliver multi-functional benefits. In July 2021, Kerry Group, an Ireland-based food company acquired Biosearch Life for a deal of $ 150 million. Through this acquisition, Kerry Group aims to expand its product portfolio in health ingredients such as probiotics and omega 3s. Biosearch Life is a Spain-based biotechnology company. Major players in the functional food market are, Unilever, BNL Food Group, Dean Foods, The Coca-Cola Company, Arla Foods, Abbott Laboratories, PepsiCo Inc., Kraft Foods Inc., and Nestle. Asia-Pacific was the largest region in the functional food market in 2022. Western Europe was the second-largest region in the global functional foods market. The regions covered in the global functional foods market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the functional food market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The functional food market consists of sales of fatty acids, carotenoids, prebiotics & probiotics, vitamins, dietary fibers, minerals, and other functional foods. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global functional foods market is segmented - 1) By Product Type: Bakery & Cereals, Dairy Products, Meat, Fish & Eggs, Soy Products, Fats & Oils, Other Product Types 2) By Ingredients: Carotenoids, Dietary Fibers, Fatty Acids, Minerals, Prebiotics & Probiotics, Vitamins, Other Ingerdients 3) By Application: Sports Nutrition, Weight Management, Immunity, Digestive Health, Clinical Nutrition, Cardio Health, Other Applications

Protein supplements refer to a nutritional supplement that contains protein and is intended to supplement the diet. A protein supplement helps in building muscle, repairing tissue, and producing enzymes and hormones. It also aids in weight loss and assists in toning of muscles for athletes. The main types of protein supplements include protein powder, protein bars, and ready-to-drink products. Protein powder refers to powdered forms of protein that are derived from plants (soybeans, peas, rice, potatoes, or hemp), eggs, or milk (casein or whey protein). Other components, such as extra sugar, artificial flavors, thickeners, vitamins, and minerals, are added to enhance the flavor and functionality of the powder. Based on raw material, the protein supplements are differentiated by casein protein supplements, whey protein supplements, egg protein supplements, MPC protein supplements, and soy protein supplements. The animal-derived and plant-derived protein supplements are sold through supermarkets, hypermarkets, online stores, and drug stores. The protein supplements market research report is one of a series of new reports from The Business Research Company that provides protein supplements market statistics, including protein supplements industry global market size, regional shares, competitors with a protein supplements market share, detailed protein supplements market segments, market trends and opportunities, and any further data you may need to thrive in the protein supplements industry. This protein supplements market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global protein supplements market size grew from $18.75 billion in 2022 to $20.62 billion in 2023 at a compound annual growth rate (CAGR) of 10.0%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services, and affecting many markets across the globe. The protein supplements market size is expected to grow to $29.51 billion in 2027 at a CAGR of 9.4%. The rise in customer preference for food supplements is driving the protein supplements market. Food Supplements are intended to make up for dietary deficiencies among individuals through their regular diet. The desire to lead active and healthy lifestyles has increased participation in sports and fitness activities, driving the demand for food supplements, especially protein supplements. According to the Council for Responsible Nutrition survey 2020, a US-based trade association for ingredient suppliers and manufacturers in the dietary supplement industry, approximately 43% of supplement users have altered their supplement regimens after the pandemic, whereas 91% of these users report an increase in supplement intake, including the addition of new supplements to an existing routine (46%), the taking of the same supplements more frequently (25%), or the increasing of doses (22%). Thus, an increase in customer preference for food supplements is expected to boost the demand for protein supplements during the forecast period. Strategic partnership is a key trend gaining popularity in the protein supplements market. The companies operating in the protein supplement sector are focusing on entering into strategic partnerships to expand their market reach and leverage each other's resources in new product development & marketing activities. In October 2021, a New Jersey-based company that creates collagen supplements entered into a partnership with Entenmann's, owed by Bimbo Bakeries USA. The partnership aims to create a new collagen protein powder with Entenmann's chocolate chip cookies as inspiration. Entenmann is a US-based company that manufactures and delivers baked goods. In February 2022, Nestle Health Sciences, a Switzerland-based provider of nutrition solutions, diagnostics devices, and drugs for specific target areas acquired a majority stake in Orgain, for an undisclosed amount. Through this, Nestle is focused on expanding its product portfolio in the plant-based protein supplement sector and enhancing its business presence in the fast-growing plant-based product sector across the globe. Orgain is a California-based provider of plant-based nutritional products. Major players in the protein supplements market are GlaxoSmithKline (GSK), Glanbia PLC, ABBOTT LABORATORIES (ABBOTT), Amway Corporation, Herbalife International of America, Inc., PepsiCo, AMCO Proteins, QuestNutrition, GNC Holdings, Maker Nutrition LLC, SUPPLEFORM, Vitaco Health Limited, Garden of Life, Melaleuca Inc., Atlantic Multipower UK Limited, International Dehydrated Foods, Inc., Scitec Nutrition, and BRF. North America was the largest region in the protein supplements market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the protein supplements market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the protein supplements market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The protein supplements market consists of sales of soybean meal, essential amino acid, protein intake, proteins, amino acids, whey protein. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global protein supplements market is segmented - 1) By Type: Protein Powder, Protein Bar, Ready to Drink 2) By Source: Plant-based, Animal-based 3) By Raw Material: Casein Protein Supplements, Whey Protein Supplements, Egg Protein Supplements, MPC Protein Supplements, Soy Protein Supplements 4) By Distribution Channel: Supermarkets & Hypermarkets, Online Stores, Drug Stores

Protein inhibitors refer to compounds that interfere with the steps directly involved in the production of new proteins in cells. Protein inhibitors operate at the ribosome level, benefiting from the significant variations between prokaryotic and eukaryotic ribosome architectures. The main product types of protein inhibitors are protein kinase inhibitors, monoclonal antibodies, and others. Monoclonal antibodies are laboratory-created molecules designed to act as substitute antibodies, restoring, enhancing, modifying, or mimicking the immune system's attack on unwanted cells, such as cancer cells. The protein inhibitors are used in the treatment of oncology, inflammatory diseases, and others, and are distributed by hospital pharmacies, independent pharmacies, and online pharmacies. The protein inhibitors market research report is one of a series of new reports from The Business Research Company that provides protein inhibitors market statistics, including protein inhibitors industry global market size, regional shares, competitors with a protein inhibitors market share, detailed protein inhibitors market segments, market trends and opportunities, and any further data you may need to thrive in the protein inhibitors industry. This protein inhibitors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global protein inhibitors market grew from $68.17 billion in 2022 to $74.3 billion in 2023 at a compound annual growth rate (CAGR) of 9.0%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The protein inhibitors market is expected to grow from $105.43 billion in 2027 at a CAGR of 9.1%. The increasing prevalence of chronic diseases is predicted to contribute to the growth of the protein inhibitors market over the forecast period. Chronic diseases such as cancer, cardiovascular diseases, and autoimmune diseases are becoming more prevalent. For instance, in May 2022, according to the World Health Organization, chronic diseases are expected to become the seventh leading cause of death globally by the end of 2030.In the USA, the number reached 157 million in 2020, with 87 million people having multiple conditions. Protein inhibitors are used for the treatment of these diseases attributing to fewer adverse effects and higher efficacy. Therefore, an increasing number of people with chronic diseases are anticipated to propel the demand for protein inhibitors market. The high cost of protein inhibitors used for cancer is anticipated to limit the growth of the protein inhibitors market shortly. Monoclonal antibodies are a type of protein made in the laboratory to bind substances in the body including cancer cells and are used to treat various types of cancer. Monoclonal antibody therapies are considered to be costlier when used for cancer. For instance, according to the National Center for Biotechnology Information, the average price of monoclonal antibodies was $96,731 for 34 monoclonal antibody indication combinations. Oncology and hematology monoclonal antibodies represented 40% of approved monoclonal antibody indication combinations, yet accounted for more than 85% of those priced at $100,000 or higher. The price of oncology or hematology monoclonal antibodies was $149,622 higher than those used in metabolic or cardiovascular disorders, $106,830 higher than in ophthalmology, $128,856 higher than in infectious diseases or allergies, and $98,981 higher than in immunology. Thus, the high cost of protein inhibitors including monoclonal antibodies for the treatment of cancer is expected to hinder the market’s growth. Companies in the protein inhibitors market are increasingly investing in various strategic initiatives such as partnerships and collaborations to develop new drugs to meet the market demand. Strategic collaborations and partnership agreements help companies to expand their existing product portfolio and geographical presence. For instance, in February 2020, Catalent, Inc., a USA-based provider of delivery technologies, drug manufacturing, gene therapies, biologics, and consumer healthcare products announced a partnership agreement with Zumutor Biologics Inc., an immune-oncology company based in the USA to manufacture ZM008, a monoclonal antibody targeting solid tumors. Moreover, in February 2021, Eli Lilly and Company, a USA-based pharmaceutical company, and Rigel Pharmaceuticals, Inc., a USA-based biotechnology company, announced a global exclusive license agreement and strategic collaboration to co-develop and commercialize Rigel's R552, a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor, for all indications, including autoimmune and inflammatory diseases. In June 2022, Pfizer Inc., a US-based pharmaceutical and biotechnology company, acquired ReViral for $525 million. The acquisition strengthens Pfizer's commitment to creating both medications and vaccines to help fight the respiratory syncytial virus while also expanding its anti-infective portfolio (RSV). ReViral is a UK-based clinical-stage biopharmaceutical company pioneering in the discovery and development of innovative antiviral drugs for disorders brought on by the respiratory syncytial virus. Major players in the protein inhibitors market are Bayer AG, Astra Zeneca, Roche, Teva, Apotex, Novartis, GlaxoSmithKline, Pfizer, Boehringer Ingelheim, and F. Hoffmann-La Roche. North America was the largest region in the protein inhibitors market in 2022. The regions covered in the global protein inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the global protein inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA. The protein inhibitors market consists of sales of erythromycin, tetracycline, chloramphenicol, and aminoglycosides. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global protein inhibitors market is segmented - 1)By Product: Protein Kinase Inhibitors, Monoclonal Antibody, Other Products 2)By Application: Oncology, Inflamatory Diseases, Other Applications 3)By Distribution Channel: Hospital Pharmacies, Independent Pharmacies, Online Pharmacies

Therapeutic proteins refer to pharmaceuticals that are genetically modified versions of human proteins that are found naturally. These powerful, quick-acting medications were developed in a lab for pharmaceutical usage. Therapeutic proteins have altered how diseases are treated since they are very effective in vivo. The main types of products in therapeutic proteins are insulin, fusion proteins, erythropoietin, interferon, human growth hormone, and follicle-stimulating hormone. Insulin is a peptide hormone produced by beta cells in the pancreatic cells that serves as the individual's primary anabolic hormone. It affects fat, carbohydrate, and protein metabolism by boosting glucose uptake from the blood into the fat, liver, and skeletal muscle cells. The different functions include enzymatic and regulatory activity, special targeting activity, vaccines, and protein diagnostics and are used in various applications such as metabolic disorders, immunologic disorders, haematological disorders, cancer, hormonal disorders, genetic disorders, and others. The therapeutic proteins market research report is one of a series of new reports from The Business Research Company that provides therapeutic proteins market statistics, including industry global market size, regional shares, competitors with a therapeutic proteins market share, detailed therapeutic proteins market segments, market trends and opportunities, and any further data you may need to thrive in the therapeutic proteins industry. This therapeutic proteins market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global therapeutic proteins market grew from $112.17 billion in 2022 to $125.74 billion in 2023 at a compound annual growth rate (CAGR) of 12.1%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The therapeutic proteins market is expected to grow from $200.43 billion in 2027 at a CAGR of 12.4%. The therapeutic proteins market is being driven by technological advancements in protein-based drug development. Therapeutic proteins cannot be synthesised chemically, they need to be produced by genetic engineering and recombinant DNA technology in living cells or organisms. Protein-engineering platform technologies such as glycoengineering, pegylation, Fc-fusion, albumin fusion, and albumin drug conjugation help to increase the production yield, product purity, circulating half-life, targeting, and functionality of therapeutic protein drugs. Belimumab, ipilimumab, taliglucerase alfa, albiglutide, and recombinant human coagulation factor IX are some therapeutic protein drugs developed using protein engineering technologies and approved by the FDA in the past five years. Increasing the number of biosimilar drugs on the global market will slow the growth of the therapeutic protein market. The patent expiration of therapeutic proteins such as monoclonal antibodies allows biosimilars to enter the market.For instance, in October 2022, Amneal Pharmaceuticals, Inc., a US-based generics and specialty pharmaceutical company, launched ALYMSYS® (bevacizumab-maly) in the United States. These cost-effective treatments, similar to the original biologics, decline the revenue and sales of therapeutic proteins. Monoclonal antibody drug approvals are increasing in the protein therapeutic segment. Chronic diseases such as cancer and immunological disorders are well treated with monoclonal antibodies. Monoclonal antibodies are a dominant and well-established product class in the protein therapeutic segment, with more safety and immunogenicity than antibodies. By overcoming the problems associated with previous antibody drugs, cell-based expression systems, such as the Chinese hamster ovary (CHO) mammalian cell expression system, have increased the productivity of monoclonal antibodies.In the last five years, the FDA has approved 213 drugs, among which 44 are monoclonal antibodies. For instance, twelve monoclonal antibodies were approved by FDA for the treatment of cancer and immunological disorders. In the United States, therapeutic protein drug manufacturers file a biologics application (BLA) with the FDA for product approval. The drug that is approved through BLA must be proven to be safe, pure, and potent.FDA consolidated review of most therapeutic proteins in the Center for Drug Evaluation and Research (CDER). In European Union, biologics are regulated by Committee for Medicinal Products for Human Use (CHMP) for marketing authorization. Eli Lilly and Company, a US-based pharmaceutical company, paid $1 billion for Protomer Technologies Inc. in July 2021.Lilly is delighted to add protomer’s breakthrough technology to its diabetes pipeline through this acquisition, since the company’s glucose-sensing insulin program, which is based on its proprietary molecular engineering of protein sensors (MEPS) platform, is exhibiting great potential. Protomer Technologies Inc. is a US-based company that specialises in next-generation protein therapies that can detect molecular activators in the body and are currently being developed. Major players in the therapeutic proteins market are Abbott Laboratories, Amgen Inc., Baxter International Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Pfizer Inc., Johnson & Johnson, and Merck & Co. Inc., Novo Nordisk A/S, and Sanofi. North America was the largest region in the therapeutic proteins market in 2022. The regions covered in the global therapeutic proteins market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the therapeutic proteins market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The therapeutic proteins market consists of sales of antibody-based drugs, FC fusion proteins, and anticoagulants. Values in this market are "factory gate values," that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The global therapeutic protein market is segmented - 1) By Product Type: Insulin, Fusion Protein, Erythropoietin, Interferon, Human Growth Hormone, Follicle Stimulating Hormone 2) By Application: Metabolic Disorders, Immunologic Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders, Other Applications 3) By Function: Enzymatic and Regulatory Activity, Special Targeting Activity, Vaccines, Protein Diagnostics